Literature DB >> 15847711

Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit.

Daniel P Petrylak1.   

Abstract

Entities:  

Year:  2005        PMID： 15847711     DOI： 10.1007/s11912-005-0074-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  3 in total

1.  [How should hormone therapy for castration-resistant prostate cancer be continued?].

Authors:  M Spahn; M Krebs
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

2.  Metastatic prostate cancer in 2015: The new and the old that is new again.

Authors:  Julie N Graff; Tomasz M Beer
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

3.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.